Generic oncology drugs: are they all safe?

The Lancet Oncology

Volumn 17, Issue 11, 2016, Pages e493-e501

  Yang, Y Tony ^a   Nagai, Sumimasa ^b   Chen, Brian K ^c,d,e   Qureshi, Zaina P ^c,d,e   Lebby, Akida A ^c,d   Kessler, Samuel ^c   Georgantopoulos, Peter ^c,d,e   Raisch, Dennis W ^c,f   Sartor, Oliver ^c,g   Hermanson, Terhi ^h   Kane, Robert C ^c,i   Hrushesky, William J ^c,e,j   Riente, Joshua J ^d   Norris, LeAnn B ^c,d   Bobolts, Laura R ^c,k,l   Armitage, James O ^m   Bennett, Charles L ^c,d,e,j  

^a GEORGE MASON UNIVERSITY   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF SOUTH CAROLINA COLLEGE OF PHARMACY   (United States)

^d WJB Dorn VA Medical Center   (United States)

^e UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ Oncology Center   (United States)

^j MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^k Oncology Analytics   (United States)

^l NOVA SOUTHEASTERN UNIVERSITY   (United States)

^m UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ECULIZUMAB; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; GEMCITABINE; GENERIC DRUG; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IFOSFAMIDE; IMATINIB; IRINOTECAN; LEVOLEUCOVORIN; LOMUSTINE; MERCAPTOPURINE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; SORAFENIB; TEMOZOLOMIDE; TRASTUZUMAB; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

BIOEQUIVALENCE; BONE PAIN; CHEMORADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; DRUG INDUSTRY; DRUG QUALITY; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; HYPERSENSITIVITY; IN VITRO STUDY; IN VIVO STUDY; LAW ENFORCEMENT; LEUKOPENIA; MUSCLE CRAMP; NEPHROTOXICITY; OPEN STUDY; PERIPHERAL NEUROPATHY; PHARMACIST; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; REVIEW; WATER RETENTION; DRUG CONTROL; THERAPEUTIC EQUIVALENCE;

ANTINEOPLASTIC AGENTS; DRUG AND NARCOTIC CONTROL; DRUGS, GENERIC; HUMANS; THERAPEUTIC EQUIVALENCY;

EID: 84995677646     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30384-9     Document Type: Review

References (74)

1. 1 Kantarjian, H, Rajkumar, SV, Why are cancer drugs so expensive in the United States, and what are the solutions?. Mayo Clin Proc 90 (2015), 500–504.
2. 2 Food and Drug Administration. Understanding generic drugs. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs, 2016 (accessed June 20, 2016).
3. 3 The Lancet Oncology. Generic drug market: growing and merging. Lancet Oncol, 16, 2015, 595.
4. 4 Allied Market Research. World oncology/cancer drugs market—opportunities and forecasts, 2013–2020. http://www.alliedmarketresearch.com/oncology-cancer-drugs-market, 2015 (accessed June 20, 2016).
5. 5 Chabner, BA, Drug shortages—a critical challenge for the generic-drug market. N Engl J Med 365 (2011), 2147–2149.
6. 6 Harris, G, Top court in India rejects Novartis drug patent. The New York Times. http://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html?_r=0, 2013 (accessed June 20, 2016).
7. 7 Sullivan, A, Sheffrin, SM, Economics: principles in action, 2003, Pearson Prentice Hall, Upper Saddle River, NJ, 471.
8. 8 International Council for Harmonisation. ICH Guidelines. http://www.ich.org/products/guidelines, 2016 (accessed June 20, 2016).
9. 9 International Generic Drug Regulators Programme. About us. http://www.igdrp.com/about-us, June, 2016 (accessed Oct 11, 2016).
10. 10 Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. http://www.fda.gov/downloads/%20Drugs/DevelopmentApprovalProcess/UCM071436.pdf, 2016 (accessed June 20, 2016).
11. 11 Davit, B, Braddy, AC, Conner, DP, Yu, LX, International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J 15 (2013), 974–990.
12. 12 Lane, EJ, China FDA lays down new guidelines on bioequivalence for generics. http://www.fiercepharma.com/manufacturing/china-fda-lays-down-new-guidelines-on-bioequivalence-for-generics, 2016 (accessed June 20, 2016).
13. 13 India Central Drugs Standard Control Organization (CDSCO). http://www.cdsco.nic.in/forms/Default.aspx, 2014 (accessed June 20, 2016).
14. 14 Health Canada. Notice: policy on bioequivalence standards for highly variable drug products. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/announce-annonce/notice-avis-be-hvdp-nb-pphv-eng.php, 2016 (accessed June 20, 2016).
15. 15 Flannery, EJ, Hutt, PB, Balancing competition and patent protection in the drug industry: The Drug Price Competition and Patent Term Restoration Act of 1984. Food Drug Cosm Law J 40 (1985), 269–309.
16. 16 Nagai, S, Ozawa, K, Regulatory approval pathways for anticancer drugs in Japan, the EU and the US. Int J Hematol 104 (2016), 73–84.
17. 17 Ministry of Health, Labour, and Welfare. Promotion of the use of generic drugs. http://www.mhlw.go.jp/english/policy_report/2012/09/120921.html, 2012 (accessed June 20, 2016).
18. 18 Kuribayashi, R, Matsuhama, M, Mikami, K, Regulation of generic drugs in Japan: the current situation and future prospects. AAPS J 17 (2015), 1312–1316.
19. 19 European Medicines Agency. Guidance on the investigation of bioequivalence. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf, 2010 (accessed June 20, 2016).
20. 20 Suthakaran, R, Regulatory process involved in generic drug approval process in USA, Europe and India. Indo Am J Pharm Res 3 (2013), 1451–1456.
21. 21 Pharmacist's Letter. State regulations on generic substitution. http://pharmacistsletter.therapeuticresearch.com/pl/ArticleDD.aspx?nidchk=1&cs=&s=PL&pt=2&segment=1186&dd=220901&AspxAutoDetectCookieSupport=1, 2009 (accessed June 20, 2016).
22. 22 National Conference of State Legislatures. Condition-specific drug substitution legislation: epilepsy. http://www.ncsl.org/research/health/rx-substitution-by-pharmacists-state-legislation.aspx, 2016 (accessed June 20, 2016).
23. 23 The Chronic Myeloid Leukemia Society of Canada. Generic imatinib: position of the CML society regarding the issue of generic imatinib in Canada. http://cmlsociety.org/generic-tyrosine-kinase-inhibitors-tkis-arrive-in-canada/, 2012 (accessed June 20, 2016).
24. 24 Information Handling Services. New generic substitution rules initiated in Japan. http://www.ihs.com/country-industry-forecasting.html?ID=106596918, 2008 (accessed June 20, 2016).
25. 25 European Generic Medicines Association. Market review. http://www.aeseg.es/restringido2/Market%20Review%202011%20%282%29.pdf, 2011 (accessed June 20, 2016).
26. 26 WHO. Chinese pharmaceutical policy studies, 2004, World Health Organization, Geneva http://archives.who.int/tbs/ChinesePharmaceuticalPolicy/BackgroundENGdefault.htm (accessed June 20, 2016).
27. 27 Singal, GL, Nanda, A, Kotwani, A, A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Ind J Pharmacol 43 (2011), 131–136.
28. 28 Counterfeit medicines: frequently asked questions, 2009, World Health Organization, Geneva http://www.who.int/medicines/services/counterfeit/faqs/QACounterfeit-October2009.pdf (accessed June 20, 2016).
29. 29 United Nations Office on Drugs and Crime. World drug report 2010. http://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf, 2010 (accessed June 20, 2016).
30. 30 Johnston, A, Holt, DW, Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol 78 (2014), 218–243.
31. 31 Qureshi, ZP, Norris, L, Sartor, O, et al. Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States. J Oncol Pract 8 (2012), 84–90.
32. 32 Food and Drug Administration. Counterfeit version of avastin in US distribution. http://www.fda.gov/Drugs/DrugSafety/ucm291960.htm, 2012 (accessed June 20, 2016).
33. 33 Vial, J, Cohen, M, Sassiat, P, Thiébaut, D, Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis. Curr Med Res Opin 24 (2008), 2019–2033.
34. 34 Poirier, E, Desbiens, C, Poirier, B, et al. Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients. Ann Pharmacother 48 (2014), 447–455.
35. 35 Garrido-Siles, M, Arenas-Villafranca, JJ, Pérez-Ruiz, E, et al. New cutaneous toxicities with generic docetaxel: are the excipients guilty?. Support Care Cancer 23 (2015), 1917–1923.
36. 36 National Cancer Institute. The “accidental” cure—platinum-based treatment for cancer: the discovery of cisplatin. http://www.cancer.gov/research/progress/discovery/cisplatin, 2014 (accessed June 20, 2016).
37. 37 Reed, E, Cisplatin and its analogues. DeVita, V, Lawrence, T, Roesnberg, S, (eds.) Cancer: principles and practice of oncology, 8th edn., 2008, Wolters Kluwer Lippincott Williams & Wilkins, Philadelphia, 419–426.
38. 38 Niho, S, Yamanaka, T, Umemura, S, et al. Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysis. Jpn J Clin Oncol 43 (2013), 390–395.
39. 39 Sekine, I, Kubota, K, Tamura, Y, et al. Innovator and generic cisplatin formulations: comparison of renal toxicity. Cancer Sci 102 (2011), 162–165.
40. 40 Oike, T, Ohno, T, Noda, SE, et al. Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy. J Radiat Res 54 (2013), 474–478.
41. 41 Dagher, R., Cohen, M, Williams, G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8 (2002), 3034–3038.
42. 42 Teva-Canada. TEVA-IMATINIB product monograph, 2013, Teva-Canada, Toronto, ON http://cmlsociety.org/wp-content/uploads/2013/10/TEVA-imatinib.pdf (accessed June 20, 2016).
43. 43 Apotex. APO-IMATINIB product monograph, 2013, Apotex, Toronto, ON http://cmlsociety.org/wp-content/uploads/2013/10/APO-imatinib.pdf (accessed June 20, 2016).
44. 44 European Medicines Agency. European Medicines Agency assessment report, 2012, Imatinib Teva, London, UK http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002585/WC500137417.pdf (accessed June 20, 2016).
45. 45 European Medicines Agency. European Medicines Agency assessment report, 2014, Imatinib Actavis, London, UK http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002594/WC500169745.pdf (accessed June 20, 2016).
46. 46 European Medicines Agency. European Medicines Agency assessment report, 2013, Imatinib Accord, London, UK http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002681/WC500145560.pdf (accessed June 20, 2016).
47. 47 Eskazan, AE, Ayer, M, Kantarcioglu, B, et al. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. Br J Haematol 167 (2014), 139–141.
48. 48 Padula, WV, Conti, RM, Larson, RA, What is the most cost-effective strategy for treating chronic myeloid leukemia after imatinib loses patent exclusivity in Europe?. Blood, 124, 2014, 738.
49. 49 Conti, RM, Padula, WV, Larson, RA, Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol 94 (2015), 249–257.
50. 50 Bollyky, T, Why chemotherapy that costs $70,000 in the US costs $2,500 in India?. http://www.theatlantic.com/health/archive/2013/04/why-chemotherapy-that-costs-70-000-in-the-us-costs-2-500-in-india/274847/, 2013 (accessed June 20, 2016).
51. 51 Kantarjian, H, The arrival of generic imatinib into the US market: an educational event. The ASCO Post. http://www.ascopost.com/issues/may-25-2016/the-arrival-of-generic-imatinib-into-the-us-market-an-educational-event/, 2016 (accessed June 20, 2016).
52. 52 Jawhari, D, Al Swisi, M, Ghannam, M, Bioavailability of a new generic formulation of imatinib mesylate 400 mg tablets versus glivec in healthy male adult volunteers. J Bioequiv Availab 3 (2012), 161–164.
53. 53 Eskazan, AE, Elverdi, T, Yalniz, FF, et al. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leuk Lymphoma 55 (2014), 2935–2937.
54. 54 Saveedra, D, Viscarra, F, Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety. Leuk Lymphoma 55 (2014), 2813–2816.
55. 55 Alwan, AF, Matti, BF, Naji, AS, Muhammed, AH, Abdulsahib, MA, Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back. Leuk Lymphoma 55 (2014), 2830–2834.
56. 56 Pharmaceuticals and Medical Devices Agency. Information on quality of generic drugs. Generic drug quality information study group meetings. July 10, 2008, to Sept 8, 2015). http://www.pmda.go.jp/safety/info-services/drugs/calling-attention/generics-info/0004.html (accessed June 20, 2016).
57. 57 Nishikawa, Y, Kajita, T, Kinezaki, M, et al. Examination of safety in changing from paraplatin for injection to carboplatin for intravenous infusion “NK”. Iryo Yakugaku 38 (2012), 708–714 (in Japanese).
58. 58 Nephropathic comparison with the starting pharmaceutical products and generic medicine of cisplatin. J Jpn Soc Hosp Pharm 51 (2015), 41–44 (in Japanese).
59. 59 Food and Drug Administration. Enforcement reports. http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm, 2016 (accessed June 20, 2016).
60. 60 Food and Drug Administration. Recalls, market withdrawals, and safety alerts. http://www.fda.gov/Safety/Recalls/default.htm, 2016 (accessed June 20, 2016).
61. 61 Alfonso-Cristancho, R, Andia, T, Barbosa, T, Watanabe, JH, Definition and classification of generic drugs across the world. Appl Health Econ Health Policy 13:suppl 1 (2015), S5–11.
62. 62 Rago L. WHO/EMRO. Bioequivalence studies: regulatory requirements on conduct and documentation of BE. WHO Prequalification Programme on Priority Essential Medicines; Cairo, Egypt; June 6–7, 2007.
63. 63 Food and Drug Administration. Warning letters and notice of violation letters to pharmaceutical companies. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm380323.htm, 2014 (accessed June 20, 2016).
64. 64 Raghavan, P, CDSCO plans surprise checks at drug manufacturing sites. http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cdsco-plans-surprise-checks-at-drug-manufacturing-sites/articleshow/51577361.cms, 2016 (accessed June 20, 2016).
65. 65 Food and Drug Administration News. FDA increasing staffing in India, China. http://www.fdanews.com/articles/171724-fda-increasing-staffing-in-china-india?v=preview, 2015 (accessed June 20, 2016).
66. 66 Food and Drug Administration. Securing the pharmaceutical supply chain. http://www.fda.gov/NewsEvents/Testimony/ucm271073.htm, 2011 (accessed June 20, 2016).
67. 67 Tremblay, J, Europe seeks drug suspensions. http://cen.acs.org/articles/93/web/2015/01/Europe-Seeks-Drug-Suspensions.html, 2015 (accessed June 20, 2016).
68. 68 Barlas, S, FDA devotes new resources to upgrading generic drug safety: but in some instances, the industry is pushing back. P T 39 (2014), 353–364.
69. 69 Harris, G, Medicines made in India set off safety worries. http://www.nytimes.com/2014/02/15/world/asia/medicines-made-in-india-set-off-safety-worries.html, 2014 (accessed June 20, 2016).
70. 70 Meredith, P, Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 25 (2003), 2875–2890.
71. 71 Van Leeuwen, RW, Van Gelder, T, Mathijssen, RH, et al. Drug-drug interactions with tyrosine-kinase inhibitors. A clinical perspective. Lancet Oncol 15 (2014), e315–e326.
72. 72 Kesselheim, AS, Gagne, JJ, Product-specific regulatory pathways to approve generic drugs: the need for follow-up studies to ensure safety and effectiveness. Drug Saf 38 (2015), 849–853.
73. 73 BCC Research LLC. Global markets for generic drugs. http://www.bccresearch.com/market-research/pharmaceuticals/generic-drugs-markets-phm009g.html, 2014 (accessed June 20, 2016).
74. 74 Jones, GH, Carrier, MA, Silver, RT, Kantarjian, H, Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood 127 (2016), 1398–1402.